Table of Content

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Digital Manufacturing for Biologics
3.3. Emerging Technologies that Support Digital Manufacturing
3.3.1. Process Analytical Technology (PAT)
3.3.2. Data Analysis Software (DAS)
3.3.3. Bioprocess Digital Twin
3.3.4. Manufacturing Execution System (MES)
3.4. Challenges Associated with the Adoption of Digital Manufacturing of Biologics
3.5. Future Perspectives

4. MARKERT LANDSCAPE
4.1. Chapter Overview
4.2. List of Process Analytical Technology (PAT) Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Type of Company
4.2.6. Analysis by Number of Platforms Offered
4.2.7. Analysis by Deployment Options
4.2.8. Analysis by Platform Capabilities
4.2.9. Analysis by Type(s) of Biologic(s) Manufactured
4.2.10. Analysis by Other Compatible Platforms
4.2.11. Analysis by Type of End User(s)
4.2.12. Analysis by Year of Establishment, Location of Headquarters and Platform Capabilities
4.2.13. Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
4.3. List of Data Analysis Software (DAS) Companies
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters (Region-wise)
4.3.4. Analysis by Location of Headquarters (Country-wise)
4.3.5. Analysis by Type of Company
4.3.6. Analysis by Number of Software Offered
4.3.7. Analysis by Deployment Options
4.3.8. Analysis by Software Capabilities
4.3.9. Analysis by Other Compatible Platforms
4.3.10. Analysis by Type of End User(s)
4.3.11. Analysis by Year of Establishment, Location of Headquarters and Software Capabilities
4.3.12. Analysis by Years of Experience, Location of Headquarters and Number of Software Capabilities (Dot-Plot Representation)
4.4. List of Manufacturing Execution System (MES) Companies
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters (Region-wise)
4.4.4. Analysis by Location of Headquarters (Country-wise)
4.4.5. Analysis by Type of Company
4.4.6. Analysis by Number of Platforms Offered
4.4.7. Analysis by Deployment Options
4.4.8. Analysis by Platform Capabilities
4.4.9. Analysis by Integrating Software
4.4.10. Analysis by Type of Service(s) Offered
4.4.11. Analysis by Analysis by Years of Experience, Location of Headquarters and Number of Platform Capabilities (Dot-Plot Representation)
4.5. List of Digital Twin Companies
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters (Region-wise)
4.5.4. Analysis by Location of Headquarters (Country-wise)
4.5.5. Analysis by Number of Platforms Offered
4.5.6. Analysis by Area(s) of Application
4.5.7. Analysis by Type of End User(s)
4.5.8. Analysis by Years of Experience, Location of Headquarters and Area(s) of Application (Dot-Plot Representation)

5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Technology Competitiveness Analysis: Process Analytical Technologies
5.4.1. Process Analytical Technologies Offered by Small Companies
5.4.2. Process Analytical Technologies Offered by Mid-sized Companies
5.4.3. Process Analytical Technologies Offered by Large Companies
5.4.4. Process Analytical Technologies Offered by Very Large Companies
5.5. Technology Competitiveness Analysis: Data Analysis Software
5.6. Technology Competitiveness Analysis: Manufacturing Execution System
5.6.1. Manufacturing Execution Systems Offered by Small Companies
5.6.2. Manufacturing Execution Systems Offered by Mid-sized Companies
5.6.3. Manufacturing Execution Systems Offered by Large and Very Large Companies
5.7. Technology Competitiveness Analysis: Digital Twins

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AspenTech
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Technology Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. FUJIFILM Diosynth Biotechnologies
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Technology Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. Merck
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Technology Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Thermo Fisher Scientific
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Technology Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Bioreactors.net
6.6.1. Company Overview
6.6.2. Technology Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Sartorius
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Technology Portfolio
6.7.4. Recent Developments and Future Outlook
6.8. Dassault Syst?mes
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Area(s) of Application
6.8.4. Recent Developments and Future Outlook
6.9. GE Healthcare
6.9.1. Company Overview
6.9.2. Technology Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. K?rber
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Technology Portfolio
6.10.4. Recent Developments and Future Outlook

7. BENCHMARKING ANALYSIS
7.1. Chapter Overview
7.2. Methodology and Key Assumptions
7.3. Competitive Benchmarking by Company Size and Region
7.3.1. Competitive Benchmarking: Small Players based in North America (Peer Group I)
7.3.2. Competitive Benchmarking: Mid-sized Players based in North America (Peer Group II)
7.3.3. Competitive Benchmarking: Large and Very Large Players based in North America (Peer Group III)
7.3.4. Competitive Benchmarking: Small Players based in Europe (Peer Group IV)
7.3.5. Competitive Benchmarking: Mid-sized Players based in Europe (Peer Group V)
7.3.6. Competitive Benchmarking: Large and Very Large Players based in Europe (Peer Group VI)
7.3.7. Competitive Benchmarking: Small, Mid-sized and Very Large Players based in Asia-Pacific (Peer Group VII)
7.4. Competitive Benchmarking: Pockets of Innovation and White Spaces

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Digital Biomanufacturing: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Technology
8.3.5. Analysis by Year of Partnership and Type of Technology
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Analysis by Geography
8.3.7.1. Intracontinental and Intercontinental Agreements
8.3.7.2. International and Local Agreements
9. MARKET CONCENTRATION ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Market Concertation Analysis: Top Digital Biomanufacturing Providers
10. INDUSTRY LIFECYCLE ANALYSIS
10.1. Chapter Overview
10.2. Industry Lifecycle Analysis
10.3. Digital Biomanufacturing: Historical Timeline of Key Events
10.4. Digital Biomanufacturing: Start-up Activity
10.5. Digital Biomanufacturing: Established Players Activity
10.6. Digital Biomanufacturing: Partnership and Collaboration Trends
10.7. Digital Biomanufacturing: Funding and Investments Trends
10.8. Current Barriers to Wider Adoption of Digitalization in Biomanufacturing
10.9. Future Outlook of Digital Biomanufacturing
10.10. Industry Lifecycle Analysis: Digital Biomanufacturing
11. MARKET FORECAST AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Digital Manufacturing Market for Biologics, 2023-2035
11.4. Digital Manufacturing Market for Biologics: Analysis by Type of Technology
11.4.1. Process Analytical Technology Market for Biologic Manufacturing, 2023-2035
11.4.2. Data Analysis Software Market for Biologic Manufacturing, 2023-2035
11.4.3. Manufacturing Execution System Market for Biologic Manufacturing, 2023-2035
11.4.4. Digital Twin Market for Biologic Manufacturing, 2023-2035
11.5. Digital Manufacturing Market for Biologics: Analysis by Type of Deployment Options
11.5.1. Market for Cloud-based Deployment Options, 2023-2035
11.5.2. Market for On-premises Deployment Options, 2023-2035
11.6. Digital Manufacturing Market for Biologics: Analysis by Type(s) of Biologic(s) Manufactured
11.6.1. Market for Antibodies, 2023-2035
11.6.2. Market for Cell and Gene Therapies, 2023-2035
11.6.3. Market for Proteins, 2023-2035
11.6.4. Market for Vaccines, 2023-2035
11.6.5. Market for Others, 2023-2035
11.7. Digital Manufacturing Market for Biologics: Analysis by Geography
11.7.1. Market in North America, 2023-2035
11.7.2. Market in Europe, 2023-2035
11.7.3. Market in Asia-Pacific, 2023-2035
11.7.4. Market in Latin America, 2023-2035
11.7.5. Market in Middle East and North Africa, 2023-2035

12. CONCLUDING REMARKS

13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. BioIntelligence Technologies
13.2.1. Interview Transcript: Joel Sirois, Chief Executive Officer and President
13.3. Yokogawa Insilico Biotechnology
13.3.1. Interview Transcript: Klaus Mauch, Managing Director and Chief Executive Officer
13.4. Aizon
13.4.1 Company Snapshot
13.4.2. Interview Transcript: Tudor Munteanu, Vice President of Operations and Strategic Initiatives
13.5. MasterControl
13.5.1 Company Snapshot
13.5.2. Interview Transcript: Ciaran O’Keeffe, Director, Business Development and Channel Sales, and Isura Sirisena, Quality and Manufacturing Digitization Specialist
13.6. Trunovate
13.6.1 Company Snapshot
13.6.2. Interview Transcript: Yaron Halfon, Director of Sales
13.7. Dassault Syst?mes
13.7.1 Company Snapshot
13.7.2. Interview Transcript: Barbara Holtz, Business Consultant

14. APPENDIX I: TABULATED DATA

15. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS